Erck Stanley C
SEC CIK 1342826 · EDGAR
BoughtSold
Most active insiders at MXCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Swirsky Douglas J | CFO | — | $8,316 |
| 2 | Ahuja Parmeet | CFO | — | — |
| 3 | Johnston John Joseph | Dir | — | — |
| 4 | Masoud Maher | Pres, CEO, Dir | — | — |
| 5 | Hemrajani Rekha | Dir | — | — |
| 6 | Al-Wakeel Yasir B. | Dir | — | — |
| 7 | Brooke William W | Dir | — | — |
| 8 | Collins Cynthia | Dir | — | — |
| 9 | Erck Stanley C | Dir | — | — |
| 10 | BALTHROP PATRICK J | Dir | — | — |
Transactions 24
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-22 16:28 | 2026-06-17 | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | A - Grant | $0.00 | +30.4K | 428.7K | +8% | $0 |
| 2025-08-13 | 2025-08-13 | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | P - Purchase | $1.37 | +100.0K | 398.3K | +34% | +$137.0K | |
| D | 2025-06-23 | 2025-06-18 | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | A - Grant | $0.00 | +29.2K | 298.3K | +11% | $0 |
| D | 2024-11-05 | 2024-11-01 | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | M - OptEx | $0.04 | +47.7K | 316.8K | +18% | +$1,908 |
| D | 2024-11-05 | 2024-11-01 | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | S - Sale+OE | $3.72 | -47.7K | 269.1K | -15% | -$177.4K |
| DM | 2024-10-02 | 2024-10-01+ | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | S - Sale+OE | $3.75 | -47.7K | 269.1K | -15% | -$178.8K |
| DM | 2024-10-02 | 2024-10-01+ | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | M - OptEx | $0.04 | +47.7K | 295.2K | +19% | +$1,908 |
| DM | 2024-09-05 | 2024-09-03+ | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | M - OptEx | $0.04 | +47.7K | 298.9K | +19% | +$1,908 |
| DM | 2024-09-05 | 2024-09-03+ | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | S - Sale+OE | $4.02 | -47.7K | 269.1K | -15% | -$191.7K |
| D | 2024-06-13 | 2024-06-11 | MXCT | MAXCYTE, INC. | Erck Stanley C | Dir | A - Grant | $0.00 | +21.4K | 269.1K | +9% | $0 |
| D | 2022-12-16 | 2022-12-14 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | — | +6,966 | 38.8K | +22% | — |
| D | 2022-12-16 | 2022-12-14 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | F - Tax | $17.23 | -2,320 | 36.5K | -6% | -$40.0K |
| D | 2022-09-28 | 2022-09-26 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | — | +6,546 | 34.0K | +24% | — |
| D | 2022-09-28 | 2022-09-26 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | F - Tax | $18.87 | -2,180 | 31.8K | -6% | -$41.1K |
| D | 2021-12-16 | 2021-12-14 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | — | +6,967 | 30.8K | +29% | — |
| D | 2021-12-16 | 2021-12-14 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | F - Tax | $168.43 | -3,366 | 27.5K | -11% | -$566.9K |
| DM | 2021-10-05 | 2021-10-01 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | $27.17 | +49.0K | 72.9K | +205% | +$1.33M |
| DM | 2021-10-05 | 2021-10-01 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | S - Sale+OE | $175.10 | -49.0K | 25.9K | -65% | -$8.58M |
| DM | 2021-10-05 | 2021-10-04 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | S - Sale+OE | $176.15 | -42.8K | 45.1K | -49% | -$7.54M |
| DM | 2021-10-05 | 2021-10-04 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | $27.45 | +42.8K | 55.9K | +328% | +$1.18M |
| D | 2021-09-28 | 2021-09-26 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | — | +6,546 | 27.0K | +32% | — |
| D | 2021-09-28 | 2021-09-26 | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | F - Tax | $248.16 | -3,162 | 23.9K | -12% | -$784.7K |
| DM | 2021-07-06 | 2021-07-01+ | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | S - Sale+OE | $214.38 | -105.2K | 21.2K | -83% | -$22.55M |
| DM | 2021-07-06 | 2021-07-01+ | NVAX | NOVAVAX INC | Erck Stanley C | Pres, CEO, Dir | M - OptEx | $71.12 | +105.2K | 73.1K | New | +$7.48M |
Purchase Sale Sale after option exercise All abbreviations